Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. reported a net loss of $33.8 million for the fiscal year ended December 31, 2025, an improvement from a net loss of $55.9 million in the prior year. The company generated no revenue, with losses driven by research and development expenses of $25.7 million and general and administrative expenses of $9.6 million. The reduction in net loss was primarily due to decreased R&D spending, which fell by $22.6 million (46.8%) year-over-year, reflecting lower clinical development and drug manufacturing costs. The company ended the period with $70.0 million in cash and cash equivalents, total assets of $72.1 million, and stockholders' equity of $44.3 million. Key forward-looking events include the FDA's PDUFA date of March 16, 2026, for the reproxalap NDA and the potential exercise of the AbbVie Option for commercialization.

Key Takeaways